

THRU ONLINE FILING

July 28, 2023

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited, Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra – (East). Mumbai-400051. Scrip Code: IPCALAB

Dear Sirs,

Re: Receipt of approval from the Competition Commission of India (CCI)

This has reference to the Public Announcement dated April 24, 2023 made by the Company as Acquirer to the shareholders of Unichem Laboratories Limited ("**Target Company**") in compliance with the provisions of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended ("**SEBI SAST Regulations**") for acquisition of upto 1,83,05,495 Equity Shares of Rs. 2/- each representing in aggregate 26% of the fully diluted voting Equity Share Capital of the Target Company, for cash at a price of Rs. 440/- per Equity Share ("**the Open Offer**").

The transactions contemplated under the Public Announcement (i.e. the acquisition of shares under the Share Purchase Agreement and the Open Offer) were subject to the receipt of the necessary approval of the Competition Commission of India ("CCI").

We are now pleased to inform you that the Company has now received on 27th July, 2023 the approval of the Competition Commission of India (CCI) for the transactions contemplated under the Public Announcement.

Update on the Open Offer

The Draft Letter of Offer (DLOF) in respect of the Open Offer was filed with SEBI on May 10, 2023 and the SEBI observations / comments on the DLOF is awaited. The updated schedule of activities pertaining to the Open Offer would be communicated separately upon receipt of the observations/comments from SEBI on DLOF.

Kindly take this on record.

Thanking you

Yours faithfully For Ipca Laboratories Limited

Harish Kamath Corporate Counsel & Company Secretary ACS6792